Logo

Abbott

Abbott Preparing for COVID-19 Testing Uncertainty in 2022
Premium

During the firm's earnings call, management emphasized how the ups and downs of the pandemic made predicting the year particularly difficult.

Abbott Q4 Diagnostics Revenues Grow 3 Percent, Full-Year Revenues up 25 Percent

The Abbott Park, Illinois-based firm's global COVID-19-related sales were $2.3 billion in the fourth quarter, including $2.1 billion from rapid testing.

JPM Healthcare Conference Day 2: Thermo Fisher, BD, SomaLogic, Myriad, Oxford Nanopore, More

Highlights of the second day included Myriad Genetics' new oncology testing service and more details on SomaLogic's partnership with Illumina.

People in the News: New Appointments at NIH, Abbott, Talis Biomedical, More

Abbott Sees Continued Demand for SARS-CoV-2 Rapid Tests Despite Expected Decline in Cases
Premium

The firm more than doubled its COVID-19 testing-related revenues during Q3 compared to a year ago. Around 84 percent of the revenues were for rapid screening tests.

Oct 20, 2021

Abbott Q3 Diagnostics Revenues Rise 48 Percent on Core Lab, Rapid Diagnostics Sales Growth

Oct 14, 2021

FDA Classifies Abbott SARS-CoV-2 Molecular Test Recall as Class I Due to False Positives

Sep 17, 2021

FDA Warns of Potential False Positives With Abbott SARS-CoV-2 Molecular Tests

Jul 22, 2021

Abbott Q2 Diagnostics Revenues Rise 63 Percent on COVID-19 Testing Demand

Jun 1, 2021

Abbott Lowers FY21 Guidance as It Sees Sharp Decline in COVID-19 Test Revenue

Apr 20, 2021

Abbott Q1 Diagnostics Revenues More Than Double on COVID-19 Testing

Mar 11, 2021

Abbott Forms Global Coalition to Monitor, Prevent Future Pandemics

Mar 5, 2021

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Feb 18, 2021

WHO Finds High Diagnostic Accuracy in Three Classes of MDx Technologies for TB Testing, Resistance

Jan 27, 2021

Abbott Q4 Diagnostics Revenues up 111 Percent, FY20 Revenues up 9 Percent

Nov 13, 2020

Abbott Enters $5B Credit Agreement

Oct 21, 2020

Abbott Q3 Diagnostics Revenues Increase 38 Percent

Oct 7, 2020

Abbott ID Now Study Data Confirms Test Sensitivity and Specificity

Sep 21, 2020

FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

Sep 8, 2020

As Flu Season Nears, Dx Companies Shift Attention to Multiplex Tests for SARS-CoV-2, Influenza
Premium

Aug 27, 2020

As Abbott Stock Rises on EUA for Antigen Test, Competitors' Shares Take a Hit

Jul 21, 2020

AdvaMed Partners With Dx Companies to Create National COVID-19 Supply Registry

Jul 17, 2020

Weathering COVID-19 Pandemic, Abbott Beats Analyst Q2 Expectations on Coronavirus Testing Demand
Premium

Jul 16, 2020

Abbott Q2 Diagnostics Revenues Rise 5 Percent, MDx Revenues Skyrocket

Jun 12, 2020

In Brief This Week: Guardant Health, Illumina, Twist Bioscience, Hologic, InCellDx, More

Breaking News
The Scan

Time to Act

A new report urges the UK to consider regulations to protect against the misuse of genomic technologies, according to the Guardian.

Fulgent Seeking Defamation Suit

Fulgent Genetics says it plans to sue Los Angeles County Sheriff Alex Villanueva for defamation, the Los Angeles Times reports.

Speeding Gene-Edited Crops

Reuters reports that China's new trial rules will make it easier to grow gene-edited crops there.

Nucleic Acids Research Papers on Viral Recombination, Pan-Cancer Mutations, SARS-CoV-2 Variability

In Nucleic Acids Research this week: updated pipeline to detect viral recombination, mutational patterns in tumor samples, and more.